Question 1

Is this actionable now?

Accepted Answer

closed. MBIE announced on 17 December 2025 that the Ārohia Trailblazer and Evidence Grant programmes were closing and that no further rounds would open. Existing contracted grants continue under their agreements, but this programme is terminated for new applicants rather than recurring or rolling.

Question 2

What is the real economic value?

Accepted Answer

The Trailblazer Grant funded up to 30% of approved eligible non-R&D market-entry costs, to a maximum of NZD 4 million over a project generally lasting no more than 24 months. The applicant had to provide the other 70%; the reviewed official corpus does not state a universal minimum Trailblazer award.

Question 3

Who is eligible?

Accepted Answer

An eligible New Zealand business with a globally novel innovation, or world-leading innovation being introduced to New Zealand, at the getting-ready-to-market stage after most difficult R&D was complete. The project needed a credible first-market route, commercial feasibility, material benefits and spillovers for New Zealand's innovation ecosystem, an approved non-R&D work plan, and 70% applicant co-funding.

Question 4

How does selection work?

Accepted Answer

During an open round, register interest and complete the eligibility screen; Prepare the full application with innovation, spillover, market, feasibility, evidence, work-plan and co-funding material; Pass eligibility and evidence checks; Receive scored assessment against novelty, ecosystem benefit, market impact, feasibility and deliverability; Pitch the application to the evaluation panel and answer questions; Complete due diligence, budget and contracting if approved; Sign the funding agreement before starting eligible activities; Deliver the approved non-R&D market-entry work and submit claims and progress evidence; Complete final reporting, cost settlement and outcome obligations; Repay funding if the agreement is breached or costs are later ruled ineligible. The active-round process included eligibility review, documentary assessment, a panel pitch, due diligence and contracting. The reviewed official sources do not state a dependable application-to-decision interval, and no further rounds will occur.

Question 5

What burden and restrictions apply?

Accepted Answer

The funding agreement requires evidence-based claims, progress and final reports, detailed records, access for audit or investigation, notice and approval for material project or control changes, publicity cooperation and compliance with the approved budget and milestones. Breach, ineligible costs, misrepresentation or termination can result in withholding, cancellation and repayment. Trailblazer funds covered only approved non-R&D activities essential to first market entry and incurred during the agreement, including customer work, detailed design, beta or field work, regulatory and compliance activity, IP activity, marketing, prototypes, commercialisation staff or contractors and eligible depreciation. R&D, business-as-usual work, post-first-sale expansion, full production runs, unrelated markets, capital-raising costs, bonuses, dividends and out-of-term spending were excluded. Complete IP ownership terms remained agreement-specific in the reviewed material.

Question 6

What evidence exists?

Accepted Answer

A 2024 ministerial speech named seven recipients—Astrix Astronautics, Emrod, Fabrum Solutions, Basis NZ, Toku Eyes, Zincovery Process Technologies and Zenno Astronautics—sharing about NZD 17.5 million in co-funding Callaghan Innovation's Alimetry profile documents grant-backed expansion to more than 30 hospitals and clinics in the United States Basis and Fabrum each published contemporaneous primary accounts confirming their Trailblazer awards and intended market or ecosystem impact A Basis recipient account says it was selected from 86 applicants, but the surviving reviewed corpus does not establish the complete number of awards from that applicant pool; a comparable program-wide acceptance rate remains unknown.

Ārohia Innovation Trailblazer Grant

Key facts

Application process

Background

How the application really works

Tips

Watch out for

Track record

Frequently asked questions

Related grants

Sources

Funder	Callaghan Innovation
Amount	The Trailblazer Grant funded up to 30% of approved eligible non-R&D market-entry costs, to a maximum of NZD 4 million over a project generally lasting no more than 24 months. The applicant had to provide the other 70%; the reviewed official corpus does not state a universal minimum Trailblazer award.
Decision time	The active-round process included eligibility review, documentary assessment, a panel pitch, due diligence and contracting. The reviewed official sources do not state a dependable application-to-decision interval, and no further rounds will occur.
Eligibility	An eligible New Zealand business with a globally novel innovation, or world-leading innovation being introduced to New Zealand, at the getting-ready-to-market stage after most difficult R&D was complete. The project needed a credible first-market route, commercial feasibility, material benefits and spillovers for New Zealand's innovation ecosystem, an approved non-R&D work plan, and 70% applicant co-funding.
Restrictions	The funding agreement requires evidence-based claims, progress and final reports, detailed records, access for audit or investigation, notice and approval for material project or control changes, publicity cooperation and compliance with the approved budget and milestones. Breach, ineligible costs, misrepresentation or termination can result in withholding, cancellation and repayment. Trailblazer funds covered only approved non-R&D activities essential to first market entry and incurred during the agreement, including customer work, detailed design, beta or field work, regulatory and compliance activity, IP activity, marketing, prototypes, commercialisation staff or contractors and eligible depreciation. R&D, business-as-usual work, post-first-sale expansion, full production runs, unrelated markets, capital-raising costs, bonuses, dividends and out-of-term spending were excluded. Complete IP ownership terms remained agreement-specific in the reviewed material.
Status	closed